Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
Showing 1760 results
December 2023
-
Featured NewsOur next eraNovartis poised to expand impact on human health as it begins next era.
-
Story Access to Healthcare
Beacon of Hope lights the way for a more equitable futureSharing Key Insights and Lessons to Accelerate Progress.
-
Story People and Culture
How I found my true purpose at Novartis -
Story People and Culture
Belonging here: How Novartis helped me come out as a transgender woman -
Story People and Culture
Mentoring matters: how we grow together at Novartis
November 2023
-
Key ReleaseNovartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D DayAd hoc announcement pursuant to Art. 53 LR ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent…
-
Media ReleaseNovartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASHLate-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2- early breast cancer, including those with node-…
-
Media ReleaseNovartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2In pivotal Phase III trials, remibrutinib – a highly selective, oral Bruton’s tyrosine kinase inhibitor – demonstrated clinically meaningful and statistically significant reduction in urticaria…
October 2023
-
Media ReleaseFDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decadeFDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21As the only IL-17A inhibitor…
-
Key ReleaseNovartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)Ad hoc announcement pursuant to Art. 53 LR Phase III ALIGN study met its primary endpoint, demonstrating superiority of atrasentan vs. placebo in proteinuria reduction at 36-week interim analysis1;…
-
Media ReleaseNovartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centersUS FDA has classified drug shortage status as resolved1Novartis capacity to produce Pluvicto will continue to grow with anticipated expansions to the manufacturing network in the US and globally More…
-
Featured NewsNovartis Financial Results – Q3 2023